Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Fresenius Medical Care AG & Co. KGaA is a leading provider of products and services for individuals undergoing dialysis due to chronic kidney failure. With a strong presence in North America and Europe, the company operates over 4,000 dialysis clinics and manufactures dialysis products, including machines and consumables. Its competitive position is bolstered by a comprehensive integrated care model that enhances patient outcomes and reduces costs.
Fresenius generates revenue primarily through its network of dialysis clinics, which provide treatment to patients with end-stage renal disease. The company benefits from pricing power due to its established market presence and the critical nature of its services. Additionally, its vertically integrated model allows for cost efficiencies and improved patient care, enhancing customer loyalty.
Changes in reimbursement rates for dialysis services from government and private payers
Growth in patient population due to rising incidence of diabetes and hypertension
Regulatory changes impacting healthcare providers
Technological advancements in dialysis treatment options
Potential regulatory changes that could affect reimbursement rates and operational practices
Technological disruption from new treatment modalities that could impact traditional dialysis services
Increased competition from other healthcare providers entering the dialysis market
Emergence of home dialysis solutions that could reduce demand for in-clinic treatments
Moderate financial risk due to existing debt levels, which could increase if interest rates rise
Pension obligations that could impact cash flow if not managed properly
moderate - The demand for dialysis services is somewhat insulated from economic cycles, but patient volumes can be affected by changes in healthcare spending and insurance coverage.
Low - While the company has some debt, its operations are not significantly impacted by interest rate changes. However, higher rates could affect overall healthcare spending and investment in new clinics.
minimal - Fresenius has a manageable debt-to-equity ratio of 0.83, indicating a stable financial position without heavy reliance on credit.
value - The stock is trading at a low price-to-sales ratio of 0.6x, appealing to value investors looking for undervalued opportunities in the healthcare sector.
moderate - The stock has shown a consistent decline over the past year, indicating some volatility, but it is less volatile than high-growth tech stocks.
